CinPhloro Pharma, a part of the CinRx portfolio, is committed to developing the initial safe, effective, and long-term treatment option for irritable bowel syndrome with predominant diarrhea (IBS-D). The company's innovative formulation, CIN-103, utilizes phloroglucinol, a small molecule approved in certain countries for alleviating symptoms of functional GI disorders. CIN-103 has been modified to address the limitations of ph...
CinPhloro Pharma, a part of the CinRx portfolio, is committed to developing the initial safe, effective, and long-term treatment option for irritable bowel syndrome with predominant diarrhea (IBS-D). The company's innovative formulation, CIN-103, utilizes phloroglucinol, a small molecule approved in certain countries for alleviating symptoms of functional GI disorders. CIN-103 has been modified to address the limitations of phloroglucinol, such as its short half-life. The formulation is designed to target multiple action points in IBS-D, including motility, secretion, pain, spasms, and inflammation.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.